The North American corporate cannabis sector has seen better days. Pandemic-galvanized sales surges are now mostly in the rearview mirror, and markets in large U.S. states and Canada have matured at a rapid clip. Despite the introduction of a new decriminalization bill, a lack of meaningful federal movement makes it feel like the industry is stuck at a crossroads.
